Analysis of data from a randomized trial finds trabeculectomy typically is the better financial bet than tube shunt surgery as a first option to treat glaucoma.
Assuming two procedures over a 1-year time horizon, TearCare demonstrated a cost-saving advantage over CsA, reducing per-patient costs by $903 annually. Patients receiving TearCare experienced an ...
Introduction The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III EXPLORER-HCM trial has demonstrated that the novel cardiac myosin inhibitor ...
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial The economic evaluation, conducted from societal ...
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial For the model, we used ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results